UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| | | |
| (State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |
(Address of principal executive offices) (Zip Code)
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| | | |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1934 (§240.12b-2 of this chapter)
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 Regulation FD Disclosure
On Tuesday December 19, 2022, India Globalization Capital (“IGC” or the “Company”) made available on its website an updated presentation on its Life Sciences business, handled by its subsidiary IGC Pharma, LLC (https://www.igcpharma.com/). IGC expects to use this presentation at conferences, business events, and meetings with analysts, investors, and others. A copy of the presentation is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.
The information furnished under Item 7.01 and Item 9.01 of this Current Report on Form 8-K, including the exhibit, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities under that Section, nor shall it be deemed incorporated by reference in any registration statement or other filings of the Company under the Securities Act of 1933, as amended, except as shall be set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
|
99.1 |
|
|
99.2 |
|
|
104 |
Cover Page Interactive Data File (embedded within the Inline XBRL document). |
About IGC:
India Globalization Capital, Inc. (“IGC” or the “Company”) through its subsidiary IGC Pharma, LLC, develops advanced cannabinoid-based formulations for treating diseases, including but not limited to Alzheimer’s disease, Parkinson’s disease, chronic pain, and pet seizures. The Company’s leading drug candidate, IGC-AD1, has demonstrated, in Alzheimer’s cell lines, the potential to be effective in suppressing or ameliorating a key protein responsible for Aβ plaques and has recently entered Phase 2 clinical trials for agitation in dementia from Alzheimer’s. The Company, though its other subsidiary HH Processors also has lines of various CBD-based consumer products such as Holief, which includes gummies and pain relief creams for women experiencing premenstrual syndrome (PMS) and dysmenorrhea (period cramps), and Sunday Seltzer, which includes a CBD-infused energy beverage – all currently available for purchase. The Company also operates an Infrastructure business based in India. The Company is headquartered in Maryland, U.S.A.
Forward-looking Statements:
This Current Report on Form 8-K contains forward-looking statements. These forward-looking statements are based largely on IGC’s expectations and are subject to several risks and uncertainties, certain of which are beyond IGC’s control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, the Company’s failure or inability to commercialize one or more of the Company’s products or technologies, including the products or formulations described in this release, or failure to obtain regulatory approval for the products or formulations, where required; general economic conditions that are less favorable than expected, including as a result of the ongoing COVID-19 pandemic; the FDA’s general position regarding cannabis- and hemp-based products; and other factors, many of which are discussed in IGC’s U.S. Securities and Exchange Commission (“SEC”) filings. IGC incorporates by reference the human trial disclosures and Risk Factors identified in its Annual Report on Form 10-K filed with the SEC on June 23, 2022, as if fully incorporated and restated herein. In light of these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will occur. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events, or otherwise.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
INDIA GLOBALIZATION CAPITAL, INC. |
|||
|
Date: December 20, 2022 |
By: |
/s/ Claudia Grimaldi |
|
|
Claudia Grimaldi |
|||
|
Vice President, CCO & PFO |
|||
Exhibit 99.1
Exhibit 99.2
IGC Announces Updated Life Sciences Presentation
POTOMAC, Md., Dec. 20, 2022 -- India Globalization Capital, Inc. (NYSE American: IGC) (“IGC” or the “Company”), today announces that a life sciences presentation has been filed with the SEC on Form 8K and is available at https://www.sec.gov/.
The presentation is also published on the Company’s website https://www.igcpharma.com, The presentation provides an overview of the Company’s initiatives in life sciences, including its focus on low-dose THC-based drug formulation and disease treatment and its various lines of cannabinoid-based consumer products.
About IGC:
India Globalization Capital, Inc. (“IGC” or the “Company”) through its subsidiary IGC Pharma, LLC, develops advanced cannabinoid-based formulations for treating diseases, including but not limited to Alzheimer’s disease, Parkinson’s disease, chronic pain, and pet seizures. The Company’s leading drug candidate, IGC-AD1, has demonstrated, in Alzheimer’s cell lines, the potential to be effective in suppressing or ameliorating a key protein responsible for Aβ plaques and has recently entered Phase 2 clinical trials for agitation in dementia from Alzheimer’s. The Company, through its other subsidiary HH Processors also has lines of various CBD-based consumer products such as Holief, which includes gummies and pain relief creams for women experiencing premenstrual syndrome (PMS) and dysmenorrhea (period cramps), and Sunday Seltzer, which includes a CBD-infused energy beverage – all currently available for purchase. The Company also operates an Infrastructure business based in India. The Company is headquartered in Maryland, USA.
Forward-Looking Statements:
This press release contains forward-looking statements. These forward-looking statements are based largely on IGC’s expectations and are subject to several risks and uncertainties, certain of which are beyond IGC’s control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, the Company’s failure or inability to commercialize one or more of its the Company’s products or technologies, including the products or formulations described in this release, or failure to obtain regulatory approval for the products or formulations, where required; general economic conditions that are less favorable than expected, including as a result of the ongoing COVID-19 pandemic; the FDA’s general position regarding cannabis- and hemp-based products; and other factors, many of which are discussed in IGC’s U.S. Securities and Exchange Commission (“SEC”) filings. IGC incorporates by reference the human trial disclosures and risk factors identified in its Annual Report on Form 10-K, filed with the SEC on June 23, 2022, as if fully incorporated and restated herein. In light of these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will occur.
Contact:
IMS Investor Relations
Walter Frank
igc@imsinvestorrelations.com
(203) 972-9200
Corporate Communications:
InvestorBrandNetwork (IBN)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com
Document And Entity Information |
Dec. 19, 2022 |
|---|---|
| Document Information Line Items | |
| Entity Registrant Name | INDIA GLOBALIZATION CAPITAL, INC. |
| Trading Symbol | IGC |
| Document Type | 8-K |
| Amendment Flag | false |
| Entity Central Index Key | 0001326205 |
| Document Period End Date | Dec. 19, 2022 |
| Entity Emerging Growth Company | false |
| Entity Incorporation, State or Country Code | MD |
| Entity File Number | 001-32830 |
| Entity Tax Identification Number | 20-2760393 |
| Entity Address, Address Line One | 10224 Falls Road |
| Entity Address, City or Town | Potomac |
| Entity Address, State or Province | MD |
| Entity Address, Postal Zip Code | 20854 |
| City Area Code | (301) |
| Local Phone Number | 983-0998 |
| Written Communications | false |
| Soliciting Material | false |
| Pre-commencement Tender Offer | false |
| Pre-commencement Issuer Tender Offer | false |
| Title of 12(b) Security | Common Stock, $.0001 par value |
| Security Exchange Name | NYSEAMER |
{
"instance": {
"indiaglob20221219_8k.htm": {
"axisCustom": 0,
"axisStandard": 0,
"baseTaxonomies": {
"http://xbrl.sec.gov/dei/2022": 22
},
"contextCount": 1,
"dts": {
"definitionLink": {
"local": [
"igc-20221219_def.xml"
]
},
"inline": {
"local": [
"indiaglob20221219_8k.htm"
]
},
"labelLink": {
"local": [
"igc-20221219_lab.xml"
]
},
"presentationLink": {
"local": [
"igc-20221219_pre.xml"
]
},
"schema": {
"local": [
"igc-20221219.xsd"
],
"remote": [
"http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
"http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
"http://www.xbrl.org/2003/xl-2003-12-31.xsd",
"http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
"http://www.xbrl.org/2005/xbrldt-2005.xsd",
"http://www.xbrl.org/2006/ref-2006-02-27.xsd",
"https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
"https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
"https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
"https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
"https://xbrl.sec.gov/sic/2022/sic-2022.xsd"
]
}
},
"elementCount": 25,
"entityCount": 1,
"hidden": {
"http://xbrl.sec.gov/dei/2022": 2,
"total": 2
},
"keyCustom": 0,
"keyStandard": 22,
"memberCustom": 0,
"memberStandard": 0,
"nsprefix": "igc",
"nsuri": "http://www.igcinc.us/20221219",
"report": {
"R1": {
"firstAnchor": {
"ancestors": [
"p",
"div",
"body",
"html"
],
"baseRef": "indiaglob20221219_8k.htm",
"contextRef": "c0",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "dei:EntityRegistrantName",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "document",
"isDefault": "true",
"longName": "000 - Document - Document And Entity Information",
"menuCat": "Cover",
"order": "1",
"role": "http://www.igcinc.us/role/DocumentAndEntityInformation",
"shortName": "Document And Entity Information",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"p",
"div",
"body",
"html"
],
"baseRef": "indiaglob20221219_8k.htm",
"contextRef": "c0",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "dei:EntityRegistrantName",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
}
},
"segmentCount": 0,
"tag": {
"dei_AmendmentFlag": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
"label": "Amendment Flag",
"terseLabel": "Amendment Flag"
}
}
},
"localname": "AmendmentFlag",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.igcinc.us/role/DocumentAndEntityInformation"
],
"xbrltype": "booleanItemType"
},
"dei_CityAreaCode": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Area code of city",
"label": "City Area Code",
"terseLabel": "City Area Code"
}
}
},
"localname": "CityAreaCode",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.igcinc.us/role/DocumentAndEntityInformation"
],
"xbrltype": "normalizedStringItemType"
},
"dei_DocumentInformationLineItems": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
}
}
},
"localname": "DocumentInformationLineItems",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.igcinc.us/role/DocumentAndEntityInformation"
],
"xbrltype": "stringItemType"
},
"dei_DocumentInformationTable": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
}
}
},
"localname": "DocumentInformationTable",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.igcinc.us/role/DocumentAndEntityInformation"
],
"xbrltype": "stringItemType"
},
"dei_DocumentPeriodEndDate": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.",
"label": "Document Period End Date",
"terseLabel": "Document Period End Date"
}
}
},
"localname": "DocumentPeriodEndDate",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.igcinc.us/role/DocumentAndEntityInformation"
],
"xbrltype": "dateItemType"
},
"dei_DocumentType": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
"label": "Document Type",
"terseLabel": "Document Type"
}
}
},
"localname": "DocumentType",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.igcinc.us/role/DocumentAndEntityInformation"
],
"xbrltype": "submissionTypeItemType"
},
"dei_EntityAddressAddressLine1": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Address Line 1 such as Attn, Building Name, Street Name",
"label": "Entity Address, Address Line One",
"terseLabel": "Entity Address, Address Line One"
}
}
},
"localname": "EntityAddressAddressLine1",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.igcinc.us/role/DocumentAndEntityInformation"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityAddressCityOrTown": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Name of the City or Town",
"label": "Entity Address, City or Town",
"terseLabel": "Entity Address, City or Town"
}
}
},
"localname": "EntityAddressCityOrTown",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.igcinc.us/role/DocumentAndEntityInformation"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityAddressPostalZipCode": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Code for the postal or zip code",
"label": "Entity Address, Postal Zip Code",
"terseLabel": "Entity Address, Postal Zip Code"
}
}
},
"localname": "EntityAddressPostalZipCode",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.igcinc.us/role/DocumentAndEntityInformation"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityAddressStateOrProvince": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Name of the state or province.",
"label": "Entity Address, State or Province",
"terseLabel": "Entity Address, State or Province"
}
}
},
"localname": "EntityAddressStateOrProvince",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.igcinc.us/role/DocumentAndEntityInformation"
],
"xbrltype": "stateOrProvinceItemType"
},
"dei_EntityCentralIndexKey": {
"auth_ref": [
"r1"
],
"lang": {
"en-us": {
"role": {
"documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
"label": "Entity Central Index Key",
"terseLabel": "Entity Central Index Key"
}
}
},
"localname": "EntityCentralIndexKey",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.igcinc.us/role/DocumentAndEntityInformation"
],
"xbrltype": "centralIndexKeyItemType"
},
"dei_EntityEmergingGrowthCompany": {
"auth_ref": [
"r1"
],
"lang": {
"en-us": {
"role": {
"documentation": "Indicate if registrant meets the emerging growth company criteria.",
"label": "Entity Emerging Growth Company",
"terseLabel": "Entity Emerging Growth Company"
}
}
},
"localname": "EntityEmergingGrowthCompany",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.igcinc.us/role/DocumentAndEntityInformation"
],
"xbrltype": "booleanItemType"
},
"dei_EntityFileNumber": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
"label": "Entity File Number",
"terseLabel": "Entity File Number"
}
}
},
"localname": "EntityFileNumber",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.igcinc.us/role/DocumentAndEntityInformation"
],
"xbrltype": "fileNumberItemType"
},
"dei_EntityIncorporationStateCountryCode": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Two-character EDGAR code representing the state or country of incorporation.",
"label": "Entity Incorporation, State or Country Code",
"terseLabel": "Entity Incorporation, State or Country Code"
}
}
},
"localname": "EntityIncorporationStateCountryCode",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.igcinc.us/role/DocumentAndEntityInformation"
],
"xbrltype": "edgarStateCountryItemType"
},
"dei_EntityRegistrantName": {
"auth_ref": [
"r1"
],
"lang": {
"en-us": {
"role": {
"documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
"label": "Entity Registrant Name",
"terseLabel": "Entity Registrant Name"
}
}
},
"localname": "EntityRegistrantName",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.igcinc.us/role/DocumentAndEntityInformation"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityTaxIdentificationNumber": {
"auth_ref": [
"r1"
],
"lang": {
"en-us": {
"role": {
"documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
"label": "Entity Tax Identification Number",
"terseLabel": "Entity Tax Identification Number"
}
}
},
"localname": "EntityTaxIdentificationNumber",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.igcinc.us/role/DocumentAndEntityInformation"
],
"xbrltype": "employerIdItemType"
},
"dei_LocalPhoneNumber": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Local phone number for entity.",
"label": "Local Phone Number",
"terseLabel": "Local Phone Number"
}
}
},
"localname": "LocalPhoneNumber",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.igcinc.us/role/DocumentAndEntityInformation"
],
"xbrltype": "normalizedStringItemType"
},
"dei_PreCommencementIssuerTenderOffer": {
"auth_ref": [
"r3"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
"label": "Pre-commencement Issuer Tender Offer",
"terseLabel": "Pre-commencement Issuer Tender Offer"
}
}
},
"localname": "PreCommencementIssuerTenderOffer",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.igcinc.us/role/DocumentAndEntityInformation"
],
"xbrltype": "booleanItemType"
},
"dei_PreCommencementTenderOffer": {
"auth_ref": [
"r4"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
"label": "Pre-commencement Tender Offer",
"terseLabel": "Pre-commencement Tender Offer"
}
}
},
"localname": "PreCommencementTenderOffer",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.igcinc.us/role/DocumentAndEntityInformation"
],
"xbrltype": "booleanItemType"
},
"dei_Security12bTitle": {
"auth_ref": [
"r0"
],
"lang": {
"en-us": {
"role": {
"documentation": "Title of a 12(b) registered security.",
"label": "Title of 12(b) Security",
"terseLabel": "Title of 12(b) Security"
}
}
},
"localname": "Security12bTitle",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.igcinc.us/role/DocumentAndEntityInformation"
],
"xbrltype": "securityTitleItemType"
},
"dei_SecurityExchangeName": {
"auth_ref": [
"r2"
],
"lang": {
"en-us": {
"role": {
"documentation": "Name of the Exchange on which a security is registered.",
"label": "Security Exchange Name",
"terseLabel": "Security Exchange Name"
}
}
},
"localname": "SecurityExchangeName",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.igcinc.us/role/DocumentAndEntityInformation"
],
"xbrltype": "edgarExchangeCodeItemType"
},
"dei_SolicitingMaterial": {
"auth_ref": [
"r5"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
"label": "Soliciting Material",
"terseLabel": "Soliciting Material"
}
}
},
"localname": "SolicitingMaterial",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.igcinc.us/role/DocumentAndEntityInformation"
],
"xbrltype": "booleanItemType"
},
"dei_TradingSymbol": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Trading symbol of an instrument as listed on an exchange.",
"label": "Trading Symbol",
"terseLabel": "Trading Symbol"
}
}
},
"localname": "TradingSymbol",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.igcinc.us/role/DocumentAndEntityInformation"
],
"xbrltype": "tradingSymbolItemType"
},
"dei_WrittenCommunications": {
"auth_ref": [
"r6"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
"label": "Written Communications",
"terseLabel": "Written Communications"
}
}
},
"localname": "WrittenCommunications",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.igcinc.us/role/DocumentAndEntityInformation"
],
"xbrltype": "booleanItemType"
},
"igc_DocumentAndEntityInformationAbstract": {
"auth_ref": [],
"localname": "DocumentAndEntityInformationAbstract",
"nsuri": "http://www.igcinc.us/20221219",
"xbrltype": "stringItemType"
}
},
"unitCount": 0
}
},
"std_ref": {
"r0": {
"Name": "Exchange Act",
"Number": "240",
"Publisher": "SEC",
"Section": "12",
"Subsection": "b",
"role": "http://www.xbrl.org/2003/role/presentationRef"
},
"r1": {
"Name": "Exchange Act",
"Number": "240",
"Publisher": "SEC",
"Section": "12",
"Subsection": "b-2",
"role": "http://www.xbrl.org/2003/role/presentationRef"
},
"r2": {
"Name": "Exchange Act",
"Number": "240",
"Publisher": "SEC",
"Section": "12",
"Subsection": "d1-1",
"role": "http://www.xbrl.org/2003/role/presentationRef"
},
"r3": {
"Name": "Exchange Act",
"Number": "240",
"Publisher": "SEC",
"Section": "13e",
"Subsection": "4c",
"role": "http://www.xbrl.org/2003/role/presentationRef"
},
"r4": {
"Name": "Exchange Act",
"Number": "240",
"Publisher": "SEC",
"Section": "14d",
"Subsection": "2b",
"role": "http://www.xbrl.org/2003/role/presentationRef"
},
"r5": {
"Name": "Exchange Act",
"Number": "240",
"Publisher": "SEC",
"Section": "14a",
"Subsection": "12",
"role": "http://www.xbrl.org/2003/role/presentationRef"
},
"r6": {
"Name": "Securities Act",
"Number": "230",
"Publisher": "SEC",
"Section": "425",
"role": "http://www.xbrl.org/2003/role/presentationRef"
}
},
"version": "2.2"
}